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Abstract
Four estrogen-functionalised copper complexes were synthesised and investigated as electrochemical active DNA binding 
and cleavage agents. These complexes strategically contain a biocompatible metal centre [Cu(II)], a planar aromatic ligand as 
DNA intercalative agent and an estradiol-derivative moiety which acts as delivery vector to target estrogen-receptor-positive 
(ER+) cancer cells. Cytotoxic activity was studied over a panel of estrogen-receptor-positive (ER+) and negative (ER−) 
human cancer cell lines by means of both 2D and 3D cell viability studies. The complexes showed high in vitro intercalative 
interaction with nuclear DNA and demonstrated to be strong DNA cleaving agents. This series of Cu compounds are potent 
anticancer agents with low and sub-micromolar  IC50 values and the cellular uptake follows the lipophilicity order meaning 
that the internalisation mainly happened via passive diffusion. Finally, the estrogen-complexes are involved in the cellular 
redox stress by stimulating the production of ROS (reactive oxygen species).
Graphic abstract
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Introduction
Copper complexes are becoming interesting developmental 
anticancer agents and many recent examples demonstrated 
the efficacy of tumour treatment with Cu-containing drugs 
[1, 2]. Copper complexes are considered as an alternative 
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to the classical platinum containing anticancer drugs (i.e., 
cisplatin, carboplatin, oxaliplatin) because copper, being an 
endogenous essential metal for most aerobic organisms, is 
better tolerated compared to exogenous metals. In addition, 
the altered copper metabolism displayed by many cancer 
cells as well as the differential response between normal and 
tumour cells to copper, laid down the rationale for the devel-
opment of copper complexes as anticancer agents. Casio-
peinas is the generic name of a group of copper complexes 
designed to be used as antineoplastics and have recently 
shown promising results as chemotherapeutic agents in ani-
mal models and clinical trials [3, 4]. Copper is involved in 
fundamental biological processes such as respiration, detoxi-
fication of ROS (reactive oxygen species) and copper-based 
drugs show a wide spectrum of action [5–12]. Copper is 
a biological redox active metal centre  (Cu2+ + 1e− → Cu+ 
E0 = 0.153 V) and it is involved in the regulation of ROS 
 (OH·,  O2−·…) via Fenton and Haber–Weiss type reactions 
that are responsible for the cleavage of the DNA back-bonds 
[13–20]. Copper plays a major role in cancer cell oxidative 
stress that can result in detrimental cellular damage includ-
ing lipid peroxidation, DNA damage, protein oxidation and 
enzyme inactivation, which in turn can lead to cell death. 
One of the pioneer examples of anticancer Cu(II) complexes 
is [Cu(phen)2]2+ (phen = 1,10-phenanthroline) reported by 
Sigman and co-workers, that showed a strong anticancer 
and nuclease activity in the presence of reducing agents 
[21, 22]. This compound also showed a strong interaction 
with DNA and it was able to intercalate between the DNA 
nucleobases due to the presence of the planar aromatic 
phenanthroline ligand. [Cu(phen)2]2+ opened the route to 
the synthesis of several metal complexes with DNA interca-
lative properties using modified phenanthroline ligands such 
as DPQ, DPPZ and DPPN (DPQ = dipyrido[3,2-f:2′,3′-h]
quinoxaline, DPPZ = dipyrido[3,2-a:2′,3′-c]phenazine, 
and DPPN = benzo[i]dipyrido[3,2-a:2′,3′-c]phenazine) 
[23–30]. These complexes showed great DNA binding 
affinity and anticancer properties but negligible selectivity 
for tumour tissues. One of the most desired properties for 
an anticancer drug is the selectivity for cancer cells and, 
furthermore, for some specific cancer tissues. Steroids are 
important delivery vectors that can be used for the selec-
tive targeting of the drugs toward the cancer cell [31]. The 
activity of estrogens, the primary female sex hormone, is 
mediated by the presence of estrogen receptors (ERs) in 
cells and ERs are over-expressed in breast, ovarian, colon 
and prostate cancers, which are termed ER+ [32, 33]. ERs 
therefore, represent interesting anticancer targets [34, 35]. 
Several cancers are estrogen-dependent (i.e., ovarian cancer) 
and estrogen derivatives are also used in the treatment of 
particular cancers. In turn, a host of strategies have been 
employed to date where derivatives of one of the three major 
endogenous estrogens (estrone, estradiol, and estriol) have 
been chemically linked to a platinum-containing anticancer 
drug [36–38] and radiopharmaceuticals [39]. Recently, we 
reported the antimicrobial and anticancer activity of steroid 
derivatives of Cu(II), Pt(II), and Au(I) complexes containing 
both the female (estradiol) and male (testosterone) steroids 
[40–42]. Here, we present the syntheses, chemical and elec-
trochemical investigation, the DNA binding and cleavage 
properties together with a detailed biological study of the 
anticancer activity on 2D and 3D cancer cell cultures of a 
series of estrogen-functionalized Cu(II) complexes with the 
general formula [Cu(N∩N)(estradiol-phen)](NO3)2, where 
(N∩N) is phenanthroline, DPQ, DPPZ and DPPN (Fig. 1). 
Some of these complexes, which display the simultaneous 
presence of both the non-toxic metal centre [copper(II)] 


























Fig. 1  Structures of the estrogen-derivatives Cu(II) complexes
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(Phen, DPQ, DPPZ and DPPN), along with the presence of 
an estrogen-derivative as a delivery vector to target cancer 
cells, showed important in vitro and in vivo antimicrobial 
activity against Staphylococcus aureus [41]. The biological 
activity is assessed using cancer cell lines expressing estro-
gen receptors (ER+) and not expressing estrogen receptors 
(ER−) with the aim of verifying the successfulness of cop-
per functionalization.
Materials and methods
All reagents and reactants were purchased from commer-
cial sources. The two sources used were Sigma-Aldrich and 
Tokyo Chemical Industry. All solvents were used without 
further purification. The THF (Tetrahydrofuran) used for the 
Sonogashira coupling reaction, was dried using four ang-
strom molecular sieves, it was then decanted into a round 
bottom flask and kept under high vacuum using a Schlenk 
line while immersed in liquid nitrogen. The THF was then 
flushed with nitrogen gas. This step was repeated a mini-
mum of three times for the Sonogashira coupling reaction. 
All NMR spectra were recorded on a Bruker Advance spec-
trometer with the probe at 293 K, operating at 500 MHz for 
the 1H and at 125 MHz for 13C{1H} nuclei. Spectra were 
recorded in  CDCl3 using  Me4Si as the internal standard. 
All chemical shifts are in ppm. Infrared (IR) spectra were 
recorded in the region 4000–400 cm−1 on a Perkin Elmer 
precisely spectrum 100 FT/IR spectrometer. The solid 
samples were run using ATR. Elemental analyses (carbon, 
hydrogen and nitrogen) were performed with a PerkinElmer 
2400 series II analyzer. ESI mass spectra were recorded in 
positive mode with a Waters LCT Premier XE Spectrometer.
Electrochemistry: Non-aqueous electrochemical analysis 
of 1 mM of the copper complexes 1–3 was carried out at 
a glassy carbon electrode (0.07 cm2) in a three electrode 
configuration with Pt wire counter and non-aqueous refer-
ence Ag/Ag+ reference electrode in 0.1 M  LiClO4/DMF 
(dimethylformamide). Glassy carbon electrodes were pre-
pared by polishing with alumina suspension on a microcloth 
followed by sonication in deionised water. Voltammograms 
were generated over the range + 1 to − 1 or − 2 V vs. Ag/
Ag+ in a deaerated solution  (N2 bubbling 10 min). Data anal-
ysis employed the third cycle of the voltammogram with 
cathodic scan direction at 100 mV s−1 in all cases.
Stability: Compound 4 was taken as reference being the 
most active. 4 was dissolved in DMF to obtain a 5 mM solu-
tion. 200 μL of this solution was diluted to 2.0 mL with 
phosphate buffer solution (pH = 7.4, [P] = 50 mM). The 
solution was kept at 37 °C and monitored by HPLC using a 
Phenomenex Luna C18 (5 μM, 100 Å, 250 mm × 4.60 mm 
i.d.) column at a flow rate of 1.0 mL/min with 280 nm UV 
detection at room temperature. The mobile phase was 80:20 




A working solution of 20.0  μM UltraPure calf-thymus 
DNA [CT-DNA, Invitrogen 15633-019, ε260 = 12,824 M 
(bp)−1  cm−1] along with 25.2 μM ethidium bromide (EtBr) 
in HEPES buffer (80 mM, pH = 7.2) and NaCl (40 mM) 
was prepared. Stock solutions of metal complexes, metal 
salts, and groove binding drugs were prepared at ~ 4.0 mM 
in DMSO (dimethylsulfoxide) and diluted further with 
ultra-pure water. 50 μL of DNA-Et working solution was 
placed in each well of a 96-well microplate with the excep-
tion of the blanks which contained 100 μL HEPES buffer. 
Serial aliquots of the tested compound were added to the 
working solutions and the volume was adjusted to 100 μL 
in each well such that the final concentration of CT-DNA 
and EtBr was 10.0 μM and 12.6 μM, respectively. The plate 
was allowed to incubate at room temperature for 1 h before 
being analyzed using a Bio-Tek synergy HT multi-mode 
microplate reader with excitation and emission wavelengths 
being set to 530 and 590 nm, respectively. Concentrations 
of the tested compounds were optimized such that fluores-
cence was 30–40% of the initial control (i.e., 50 μL work-
ing solution + 50 μL HEPES buffer) at their highest read-
ing. Each drug concentration was measured in triplicate, on 
at least two separate occasions, and the apparent binding 
constants were calculated using Kapp = Ke × 12.6/C50 where 
Ke = 9.5 × 106 M (bp)−1.
DNA–ethidium fluorescence quenching
A working solution of 50.0  μM UltraPure calf-thymus 
DNA [CT-DNA, Invitrogen 15633 019, ε260 = 12,824 M 
(bp)−1 cm−1] along with either 10.0 μM ethidium bromide 
(EtBr) or Hoechst 33258 (Sigma) in HEPES buffer (80 mM, 
pH = 7.2) and NaCl (40 mM) was prepared. Stock solutions 
of metal complexes, metal salts, free ligands and groove 
binding drugs were prepared at ~ 4.0 mM in DMSO and 
diluted further with ultra-pure water. 50 μL of DNA-Et or 
DNA-Hoechst working solution were placed in each well 
of a 96-well microplate with the exception of the blanks 
which contained 100 μL HEPES buffer and 5 μM of either 
Hoechst or EtBr. Serial aliquots of the tested compound 
were added to the working solutions and the volume was 
adjusted to 100 μL in each well such that the final concen-
trations of CT-DNA and EtBr/Hoechst were 25.0 μM and 
5 μM, respectively. The plate was allowed to incubate at 
room temperature for 5 min before being analyzed using 
a Bio-Tek synergy HT multi-mode microplate reader with 
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excitation and emission wavelengths being set to 530 and 
590 nm for Et detection or 360 nm and 460 nm for Hoechst 
33258 detection. Concentrations of the tested compounds 
were optimized such that fluorescence was 30–40% of the 
initial control at their highest reading. Each drug concen-
tration was measured in triplicate, on at least two separate 
occasions. From a plot of fluorescence versus added drug 
concentration, the Q value is given by the concentration 
required to effect 50% removal of the initial fluorescence 
of bound dye.
Viscosity experiments
Fifteen mL dsDNA (deoxyribonucleic acid sodium salt from 
Salmon Testes, Sigma-Aldrich, D1626-1G) solution was 
prepared at 1 × 10−3 M in 80 mM HEPES buffer for each 
working sample.
Stock solutions prepared in DMSO were added according 
to the gradual increasing [drug]/[DNA] (r) ratios of 0.025, 
0.05, 0.075, 0.1, 0.125, 0.15, 0.175 and 0.2. Viscosity val-
ues, η, (unit: cP) were directly obtained by running 0# spin-
dle in working samples at 60 rpm via DV-II-programmable 
digital viscometer equipped with enhanced brookfield UL 
Adapter at room temperature. Data were presented as η/ηo 
versus [compound]/[DNA] ratio, in which ηo and η refers to 
viscosity of each DNA working sample in the absence and 
presence of complex.
Nuclease activity
Reactions were carried according to the literature proce-
dure [29]. Briefly, in a total volume of 20 μL using 80 mL 
of HEPES buffer (Fisher) at pH 7.2 with 25 mM NaCl, 
an aliquot of the stock complex (prepared in DMSO) was 
mixed with 400 ng of pUC19 (Roche) and 1 μL of 20 mM 
Na-l-ascorbate. Samples were incubated at 37 °C for 3 h 
before being quenched with 6× loading dye (Fermentas), 
containing 10 mM Tris–HCl (pH 7.6), 0.03% bromophenol 
blue, 0.03% xylene cyanol, 60% glycerol and 60 mM EDTA, 
then loaded onto agarose gel 1% containing 2.0 μL of Gel-
RedTM (10000×). Electrophoresis was completed at 80 V 
for 1.5 h using a wide mini-sub cell (Bio-Rad) in 1XTAE 
buffer (Millipore).
Biological studies
Copper complexes 1–4 were dissolved in the minimum 
DMSO amount prior to cell culture testing. A calculated 
amount of the stock drug DMSO solution was added to the 
cell culture media to reach a final maximum DMSO con-
centration of 0.5%, which had no effects on cell viability. 
Cisplatin was dissolved in 0.9% sodium chloride solution. 
MTT [3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium 
bromide], cisplatin and ImmunoPure p-nitrophenyl phos-
phate (APH) were obtained from Sigma Chemical Co, St. 
Louis, USA.
Cell cultures
Human colon (HCT-15) and breast (MCF-7) carcinoma cell 
lines were obtained from American Type Culture Collec-
tion (ATCC, Rockville, MD). Human ovarian 2008 cancer 
cells were kindly provided by Prof. G. Marverti (Dept. of 
Biomedical Science of Modena University, Italy). Human 
ovarian A2780 cancer cells were kindly provided by Prof. 
M.P.Rigobello (Dept. of Biomedical Science of Padova 
University, Italy). Human squamous cervical A431 carci-
noma cells were kindly provided by Prof. F. Zunino (Divi-
sion of Experimental Oncology B, Istituto Nazionale dei 
Tumori, Milan, Italy). Cell lines were maintained in the 
logarithmic phase at 37  °C in a 5% carbon dioxide atmos-
phere using RPMI-1640 medium (Euroclone) containing 
10% foetal calf serum (Euroclone, Milan, Italy), antibiotics 
(50 units mL−1 penicillin and 50 μg mL−1 streptomycin), 
and 2 mM l-glutamine.
Spheroid cultures
Spheroids were initiated in liquid overlay by seeding 
1.5 × 103 A2780 or HCT-15 cells/well in phenol red free 
RPMI-1640 medium (Sigma Chemical Co.), containing 
10% FCS and supplemented with 20% methyl cellulose 
stock solution. A total of 150 μL of this cell suspension was 
transferred to each well of a round bottom non-tissue culture 
treated 96-well plate (Greiner Bio-one, Kremsmünster, Aus-
tria) to allow spheroid formation within 72 h.
Cytotoxicity assays
MTT assay
The growth inhibitory effect towards adherent cancer 
cell lines was evaluated by means of MTT assay. Briefly, 
3–8 × 103 cells/well, dependent upon the growth character-
istics of the cell line, were seeded in 96-well microplates 
in growth medium (100 μL). After 24 h, the medium was 
removed and replaced with fresh media containing the com-
pound to be studied at the appropriate concentration. Trip-
licate cultures were established for each treatment. After 
72 h, each well was treated with 10 μL of a 5 mg mL−1 
MTT saline solution, and after additional 5 h of incubation, 
100 μL of a sodium dodecylsulfate (SDS) solution in HCl 
0.01 M were added. Following an overnight incubation, cell 
growth inhibition was detected by measuring the absorb-
ance of each well at 570 nm using a Bio-Rad 680 microplate 
reader. Mean absorbance for each drug dose was expressed 
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as a percentage of the absorbance of the untreated control 
well and plotted vs drug concentration.  IC50 values, the drug 
concentrations that reduce the mean absorbance at 570 nm to 
50% of those in the untreated control wells, were calculated 
by four parameters logistic (4-PL) model. All the values are 
the means ± SD of not less than five measurements starting 
from three different cell cultures.
Acid phosphatase (APH) assay
An APH-modified assay was used for determining cell 
viability in 3D spheroids. Briefly, the pre-seeded spheroids 
were treated with fresh medium containing the compound to 
be studied at the appropriate concentration. Triplicate cul-
tures were established for each treatment. After 72 h, each 
well was treated with 100 μL of the assay buffer (0.1 M 
sodium acetate, 0.1% Triton-X-100, supplemented with 
ImmunoPure p-nitrophenyl phosphate) and, following 3 h 
of incubation, 10 μL of 1 M NaOH solution was added. The 
inhibition of the cell growth induced by the tested complexes 
was detected by measuring the absorbance of each well at 
405 nm, using a Bio-Rad 680 microplate reader. Mean 
absorbance for each drug dose was expressed as a percentage 
of the untreated control well absorbance (T/C) and plotted vs 
drug concentration.  IC50 values, the drug concentrations that 
reduce the mean absorbance at 405 nm 50% of those in the 
untreated control wells, were calculated by four parameter 
logistic (4-PL) model. Evaluation was based on means from 
at least four independent experiments.
Cellular uptake and DNA binding
A2780 and HCT-15 cells (3 × 106) were seeded in 75 cm2 
flasks in growth medium (20 mL). After overnight incuba-
tion, the medium was replaced and the cells were treated 
with tested compounds for 24 h. Cell monolayers were 
washed twice with cold PBS, harvested and counted. Sam-
ples were than subjected to three freezing/thawing cycles at 
− 80 °C, and then vigorously vortexed. The samples were 
treated with highly pure nitric acid (Cu: ≤ 0.5 μg kg−1, 
 TraceSELECT® Ultra, Sigma Chemical Co.) and transferred 
into a microwave Teflon vessel. Subsequently, samples 
were submitted to standard procedures using a speed wave 
MWS-3 Berghof instrument (Eningen, Germany). After 
cooling, each mineralized sample was analyzed for platinum 
using a Varian AA Duo graphite furnace atomic absorption 
spectrometer (Varian, Palo Alto, CA; USA) at the wave-
length of 324 nm. The calibration curve was obtained using 
known concentrations of standard solutions purchased from 
Sigma Chemical Co. purchased from Sigma Chemical Co.
For DNA binding studies, DNA was extracted and puri-
fied by a commercial spin column quantification kit (Qia-
gen DNeasy Blood and Tissue Kit). Only highly purified 
samples (A260/A230·1.8 and A280/A260·2.0) were included 
for analysis to avoid any artefacts. The samples were com-
pletely dried and re-dissolved in 200 μL of Milli-Q water 
(18.2 MΏ) for at least 20 min at 65 °C in a shaking thermo-
mixer, mineralized and analyzed for total Cu content by GF-
AAS as described above.
Reactive oxygen species (ROS) production
The production of ROS was measured in A2780 cells 
 (104 per well) grown for 24 h in a 96-well plate in RPMI 
medium without phenol red (Sigma Chemical Co.). Cells 
were then washed with PBS and loaded with 10 μM 5-(and-
6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate 
acetyl ester (CM–H2DCFDA) (Molecular Probes-Invitrogen, 
Eugene, OR) for 25 min, in the dark. Afterwards, cells were 
washed with PBS and incubated with tested compounds. 
Fluorescence increase was estimated utilizing the wave-
lengths of 485 nm (excitation) and 527 nm (emission) in a 
Fluoroskan Ascent FL (Labsystem, Finland) plate reader. 
Antimycin (3 μM, Sigma Chemical Co), a potent inhibitor 
of Complex III in the electron transport chain, was used as 
positive control.
Comet assay
About 4 × 104 A2780 cells were seeded in 25 cm2 flasks in 
growth medium (6 mL). After 24 h, cells were incubated for 
3 h with 2.5 µM of tested compounds. Cells were washed 
twice with cold PBS, harvested, centrifuged, and DNA 
fragmentation was measured by the alkaline comet assay. 
Low melting point agarose, 300 μL (Trevigen Inc., Gaith-
ersburg, MD, US) was heated to 37  °C and combined with 
2 × 105 cells per mL cell suspension. Each well of a 20-well 
CometSlide was filled with 30 μL of the cell/agarose sus-
pension. The slides were placed in a 4  °C refrigerator in 
the dark for 15 min to solidify. Slides were then immersed 
in 50 mL of pre-chilled lysis solution containing Trizma 
base, Triton-X-100, DMSO and left at 4  °C for 30 min to 
facilitate cell membrane and histone removal. After drain-
ing excess liquid, the slides were transferred to 50 mL of 
freshly prepared (same day) alkaline DNA unwinding solu-
tion, (200 mmol L−1 NaOH, 1 mmol L−1 EDTA, pH > 13) 
and incubated at room temperature in the dark for 20 min. 
After the unwinding step, electrophoresis was performed 
at 21 V for 30 min. Slides were then rinsed with distilled 
water and fixed for 5 min in 70% ethanol. Slides were dried 
and stained for 5 min at 4  °C with SYBR Green I (Trevi-
gen, Inc.,) diluted 1:10 000 in 10 mmol L−1 Tris pH 7.5, 
1 mmol L−1 EDTA, drained to remove excess staining solu-
tion and thoroughly dried at room temperature in the dark.
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Results and discussion
The complexes were synthesised as described in the Sup-
porting Information (Scheme 1S). Phenanthroline-5-ethy-
nylestradiol (A) is obtained using Sonogashira coupling 
reaction between 5-bromophenanthroline and ethynyle-
stradiol (Scheme 1).
These kinds of reactions require extreme dry and 
degassed conditions and inert atmosphere; the reaction was 
optimized using milder conditions with respect to what 
was recently reported by us [41]. The yield and purity of 
the final product highly depend on the catalyst [Pd(PPh3)4] 
which must be freshly prepared (See Supporting Infor-
mation) and stored under argon at − 20 °C. Briefly, A is 
synthesised by coupling 5-bromophenanthroline and ethy-
nylestradiol in dry THF with 3% of [Pd(PPh3)4] as cata-
lyst and diisopropylamine (DIPA) as a base. The replace-
ment of  K2CO3 with the DIPA for the base and of DMF 
with THF for the solvent, allowed the reaction to work 
at r.t. with the formation of less impurities. The reaction 
success is evident by the disappearance of the alkyne 
proton resonance at 2.6 ppm in the 1H-NMR spectrum 
of A (Fig. 1S). Phenanthroline-5-ethynylestradiol (A), 
after purification, is mixed in a stoichiometric ratio 1:1 
with the correspondent [Cu(N∩N)(OH2)2](NO3)2 (B–E) 
(Scheme 1S), obtaining the final complexes 1–4 (Fig. 1, 
where N∩N = phen—1; N∩N = DPQ—2; N∩N = DPPZ—3 
and N∩N = DPPN—4), as described in detail in the SI. The 
complexes 1–4, characterized with IR, El. analyses, mass 
spectrometry, were stable up to 1 week in saline solution 
(0.9% NaCl). The electrochemical behavior of complexes 
1–3 was investigated and Table 1 summarises the elec-
trochemical data generated. All compounds exhibited a 
quasi-reversible wave when examined over the potential 
range 1 to − 1 V, being ascribed to the  Cu2+/1+ redox pro-
cess (Fig. 1). No clear trend was evident with respect to 
 Cu2+/1+ E1/2 values for the series 1–3, all of which fell 
within a similar interval (− 0.29 to − 0.27 V vs. Ag/Ag+) 
that is within the biological range (− 0.2–0.4 V) and they 
are likely to undergo reduction  (Cu2+ + 1e− → Cu1+) in 
physiological cell environment [43]. The relatively posi-
tive shift in all values for these complexes relative to that 
of the starting materials [Cu(N∩N)(OH2)2](NO3)2] B–D 
with E1/2 values − 0.456 V (phen), − 0.363 V (DPQ) and 
− 0.311 V (DPPZ), may reflect the electron donating con-
tribution of the estradiol conjugate and geometric altera-
tions upon reduction of the  Cu2+ centres in 1–3 to the  Cu+ 
forms. Thus, the processes may be influenced by steric 
effects of the ligands which overshadow electronic effects 
[44, 45]. The ΔEp values of the metal processes indicate 
a significant departure from a one electron reversible pro-
cess, with the possibility of coupled chemical reactions 
and the geometric reorganisation which may accompany 
the  Cu2+/1+ redox system. All Ip(a)/Ip(c) ratios are close to 
unity for the diffusion-controlled metal process. When the 
cathodic limit was extended to − 2.0 V vs. Ag/Ag+ the 
metal underwent further one electron reduction  Cu1+/0 
with subsequent ligand dissociation and (in some cases) 
re-oxidation (stripping) of plated copper back to  Cu+ 
upon anodic switching [45]. The quasi reversibility of the 
 Cu2+/1+ metal processes (cathodic limit − 1 V vs. Ag/Ag+) 
indicates little structural change prior to this point, after 
which it is likely that the complexes undergo decomposi-
tion. In the case of compounds 1 and 2, a significant anodic 
shift in the Ep(c) values for the phenanthroline and DPQ 
ligands was evident (− 1.99 V to − 1.3 V and − 1.92 V to 
− 1.37 V, respectively). This may reflect a stabilisation 
of the LUMO state of the ligands, due in this case to the 
presence of the estradiol group, resulting in a more facile 
ligand reduction process. The electrochemical behaviour 
of natural and synthetic estrogens has been reported [46, 
47] with ease of oxidation of the phenol group to the phe-
noxonium ion (a two electron process) being dependent 
on ring substitution and the solvent–electrolyte system. 
In these complexes, no estradiol anodic process is visible 
over the range examined, though clearly the presence of 
the steroid group influenced the phen, DPQ and DPPZ 
electrochemistry (Fig. 2; Table 1).  
Scheme 1  Sonogashira cou-
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Binding affinity to calf‑thymus and salmon testes 
DNA
The DNA binding affinity of the series of complexes was 
determined with calf-thymus and salmon testes duplex 
DNA polymers using a high throughput ethidium bromide 
and Hoechst 33258 fluorescence quenching assay [30], 
competition assay, and viscosity analyses (Fig. 3). The 
presence of modified phen ligands significantly enhanced 
the ctDNA binding affinity with Kapp (apparent DNA bind-
ing constant) values rising from 7 × 106 M (bp)−1 for com-
plex 1 (phen) to ~ 107 M (bp)−1 for complexes 2 and 3 
(DPQ and DPPZ, respectively). Both phenazine complexes 
had a binding affinity comparable to a reference interca-
lating antibiotic, Actinomycin D (3 × 107 M (bp)−1) [28]. 
Complex 4, containing the extended phenazine substituent 
DPPN, had a lower binding constant of ~ 5 × 106 M (bp)−1 
(Table 2), an effect previously observed with copper(II) 
ternary complexes [29]. Fluorescence quenching (Q) of 
limited Hoechst 33258 (minor groove binder) and ethidium 
bromide (intercalator) bound ctDNA shows the complex 
series were not selective in displacing these fluorophores, 
however, a similar trend was observed in the displacement 
of both reporters: 3 > 2 > 1 > 4 (Table 2). Viscosity analy-
sis with salmon testes duplex DNA confirmed complex 
3, containing the DPPZ ligand, as a strong intercalator 
and this hydrodynamic profile was followed by complex 2 
(DPQ) and then 1 (phen, which presumably kinks DNA) 
[48]. Complex 4 with the larger DPPN ligand again dis-
played attenuated activity (Table 2). Moving from phen 
to DPQ and DPPZ the planarity and aromaticity of the 
ligands are optimized for DNA intercalation but the further 
modification to DPPN leads to steric hindrance thereby 
preventing efficient DNA binding [49, 50].
The DNA-cleavage ability of the Cu(II) complexes was 
measured by monitoring the conversion of SC-DNA (form 
I) to the nicked-circular form (NC, form II) using agarose 
gel electrophoresis (Fig. 4). SC pUC19 DNA (400 ng) was 
incubated with increasing complex concentrations (range 
0.5–20 μM) in the presence of Na-l-ascorbate (1 mM) for 
3 h. All complexes had the ability to convert SC-DNA into 
the nicked form at 1 μM but complex 3, the DPPZ-contain-
ing complex, displayed the highest cleavage potency being 
able to cleave plasmid DNA already at 0.5 μM concentra-
tion. In absence of Na-l-ascorbate no detectable cleavage 
was observed.
With the aim of evaluating the antitumor potential of 
the newly developed Cu(II) complexes 1–4, and to verify 
if they are more effective in targeting ER+ cell lines with 
respect to ER− ones, their in vitro antitumor potential 
was assessed in a panel of ER+ human cancer cell lines, 
A431 (cervical), MCF-7 (breast), 2008 (ovarian) and 
A2780 (ovarian) cancer cells as well as against ER- HCT-
15 colon cancer cells. Cells were exposed to the tested 
compounds for 72 h and the  IC50 values, calculated from 
the dose–response curves, are reported in Table 3. The 
stability of complex 4 in phosphate buffer solution (37 °C, 
pH 7.4) was previously evaluated via HPLC to confirm 
that the estrogen moiety, that can be carcinogenic being 
a steroid, is not released from the coordination sphere of 
the metal centre. Figure 3S reports the chromatograms 















Fig. 2  Cyclic voltammogram of 1 mM solution of complexes 1–3 at 
a glassy carbon electrode (0.07  cm2) in a three electrode configura-
tion with Pt wire counter and non-aqueous reference Ag/Ag+ refer-
ence electrode in 0.1  M  LiClO4/DMF. Scan rate 100  mV  s−1 over 
the potential range + 1 to − 1 V vs. Ag/Ag+. Background electrolyte 
(green circle), (1) (blue circle) (2) (red circle) (3) (black circle)
Table 1  Electrochemical data 
for complexes 1–3 
Complex Cathodic 
limit (V)
Cu(I/II) Cu(0/I) Ligand redox process
E1/2 (V) ∆Ep (V) Ip(a)/Ip(c) Ep(c) (V) Ep(a) (V) Ep(c) (V) E1/2 (V) ∆Ep (V)
1 − 1 − 0.2769 0.198 0.85 – – – – –
− 2 – – – – – − 1.3 – –
2 − 1 − 0.272 0.296 1 – – – – –
− 2 – – – – – − 1.37 – –
3 − 1 − 0.287 0.225 0.84 – – – – –
− 2 − 1.17 -1.365 − 1.475 − 1.42 0.11
− 2 − 1.845
56 JBIC Journal of Biological Inorganic Chemistry (2020) 25:49–60
1 3
Fig. 3  Binding of complexes 1 (blue circle), 2 (orange circle), 3 (gray 
circle), and 4 (yellow circle) to A ethidium bromide saturated solu-
tion of dsDNA (ctDNA); B and C fluorescence quenching of limited 
ethidium bromide or Hoechst 33258 bound ds DNA (ctDNA) upon 
titration of complexes; D viscosity properties of complex treated 
salmon testes dsDNA
Table 2  DNA binding 
properties of complexes 1–4 
a C50 = concentration required to reduce fluorescence by 50%
b Kapp = Ke × 12.6/C50 where Ke = 9.5 × 106 M (bp−1)
c Reduction of 50% initial fluorescence from DNA-bound dye by tested compound (μM)
d Relative viscosity value at r = 0.20
Complex C50 (μM)a Kapp M(bp−1)b Q (EtBr, μM)c Q (Hoechst, 
μM)c
n/n0 (r = 0.2)d
1 16.13 7.21 × 106 21.5 16.4 1.12
2 12.70 9.43 × 106 15.1 12.9 1.19
3 8.32 1.44 × 107 12.5 9.29 1.25
4 21.50 5.57 × 106 37.6 26.1 1.06
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of 4 immediately upon dissolution and after 72 h where 
it is clearly visible that the complex is highly stable with 
negligible amount of steroid released.
All the complexes promoted a significant cytotoxic 
activity, with  IC50 values in the low-/sub-micromolar range 
against all cancer cell lines tested. In general, all deriva-
tives were more effective in inducing cancer cell death 
with respect to the reference metallodrug cisplatin. Among 
the newly developed Cu(II) compounds, 3 and 4 were the 
most potent derivatives, with  IC50 calculated towards all 
tested cancer cells in the sub-micromolar range. These data 
indicate that by increasing the lipophilicity of the diamine 
ligand in turn increased the cytotoxic activity of the related 
copper(II) complex. On the other hand, complexes 1–3 
displayed equally cytotoxic properties against ER+ and 
ER− cancer cells, thus suggesting the inability of these com-
plexes to selectively target ER+ cancer cells. Conversely, 
4 proved to be slightly more effective against ER+ A2780 
ovarian cancer cells.
The in vitro antitumor potential of the Cu(II) complexes 
was also examined in 3D cell culture models of ovarian 
(ER+) and colon (ER−) cancers. Actually, even if the 2D 
cell cultures is the most used in vitro method for screen-
ing of potential therapeutics due to its simplicity, reproduc-
ibility, and low cost, this method is unable to reproduce the 
properties of in vivo solid tumors. 3D cell cultures, possess-
ing several features that more closely mimic the heteroge-
neity and complexity of in vivo tumors, are recognized to 
be more predictive for in vivo results than conventional 2D 
cell cultures [51]. The cancer spheroids were treated with 
copper(II) complexes or cisplatin for 72 h and cell viability 
was assessed by means of the acid phosphatase (APH) assay 
(Table 4).
These tested non-proliferative and very resistant tumour 
models, 1–4 were extremely effective, being more active 
than cisplatin against both A2780 ovarian and HCT-15 colon 
cancer cell spheroids. In particular, 3 and 4 were confirmed 
as the most potent derivatives, being about 30 and 9 times 
more effective than cisplatin in A2780 and HCT-15 3D cell 
cultures, respectively.
Complexes 1–3 showed a similar activity toward ER+ and 
ER− cancer cells, thus confirming the results obtained in 
the 2D system and supporting the hypothesis of their inabil-
ity to selectively target ER+ cancer cells. On the contrary, 
in 3D systems, compound 4 again showed a certain degree 
of selectivity towards A2780 cancer cells, being about 3 
times more effective in ER+ human ovarian cancer cells 
with respect to ER− human colon cancer cells. With the 
aim of identifying a possible correlation between cytotoxic 
Fig. 4  DNA cleavage. Agarose 
gel electrophoresis patterns of 
SC pUC19 DNA incubated with 
complexes 1–4 (0.5–20 μM) in 
HEPES buffer at 37 °C for 3 h
Table 3  In vitro cytotoxic activity of complexes 1-4 
Cells (3–8  ×  103  mL−1) were treated for 72  h with increasing con-
centrations of the tested compounds. Cytotoxicity is assessed by MTT 
test.  IC50 values (µM) were calculated by a four parameter logistic 
model (p < 0.05)
SD standard deviation
IC50 (µM) ± SD
A2780 2008 A431 MCF-7 HCT-15
1 0.6 ± 0.1 1.5 ± 0.7 1.3 ± 0.3 1.0 ± 0.2 0.8 ± 0.3
2 0.3 ± 0.02 1.6 ± 0.4 2.0 ± 0.4 1.2 ± 0.3 0.8 ± 0.1
3 0.1 ± 0.04 0.2 ± 0.1 0.1 ± 0.1 0.7 ± 0.2 0.5 ± 0.2
4 0.04 ± 0.01 0.6 ± 0.03 0.3 ± 0.03 0.9 ± 0.2 0.5 ± 0.2
Cisplatin 2.6 ± 0.8 2.2 ± 0.6 1.7 ± 0.3 7.6 ± 0.2 13.9 ± 1.7
Table 4  In vitro cytotoxicity against ovarian and colon cancer cell 
spheroids
Spheroids (1.5 × 103  cells/well) are treated for 72  h with increasing 
concentrations of test compounds. The growth inhibitory effect was 
evaluated by means of the APH test.  IC50 values were calculated 
from the dose-survival curves by the four parameter logistic model 
(p < 0.05)
SD standard deviation
IC50 (µM) ± SD
A2780 HCT15
1 10.6 ± 1.0 7.7 ± 1.6
2 7.7 ± 1.0 9.9 ± 1.0
3 4.1 ± 0.1 9.2 ± 0.6
4 3.0 ± 0.02 8.6 ± 0.5
Cisplatin 91.3 ± 5.4 68.3 ± 2.1
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activity and cellular accumulation, cellular copper content 
was measured in ER+ A2780 and ER− HCT-15 cancer cells 
treated for 24 h with equimolar concentrations of the tested 
compounds. The cellular copper levels were quantified by 
means of GF-AAS analysis, and the results, expressed as ng 
Cu per  106 cells, are shown in Fig. 5A.
Although to a different extent, all derivatives were able to 
cross the cancer cell membrane and enter cancer cells. Com-
plexes 1–3 were able to similarly accumulate into ovarian and 
colon cancer cells, whereas derivative 4 was significantly more 
effective in entering ER+ A2780 cancer cells. Interestingly, 4 
accumulated in a time-dependent manner, actually both ovar-
ian and colon cancer cells displayed a time-dependent increase 
in cellular copper content (Fig. 5B). By matching cytotoxic 
activity data with those arising from cellular uptake quantifi-
cation, a linear and direct correlation is evidenced (Fig. 4S).
Copper species have been regarded as redox active 
compounds and it was shown that copper complexes may 
catalyze the reaction of hydrogen peroxide in the form of 
Fenton-like reactions inside the cell to produce ROS, thus 
altering cellular redox homeostasis and driving cells towards 
oxidative stress. On these bases, we evaluated cellular ROS 
levels in A2780 cells treated with 10 μM of the most effec-
tive complex 4. ROS production was monitored using 
the peroxide-sensitive fluorescent probe CM-H2DCFDA 
[5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein 
diacetate, acetyl ester]. Antimycin, a classical inhibitor of 
the mitochondrial respiratory chain at the level of complex 
III, was used as a positive control.
The results, expressed as arbitrary units of fluorescence 
as a function of time, are shown in Fig. 6A. Interestingly, 
4 was able to substantially stimulate the production of 
hydrogen peroxide in a time-dependent manner, to a rather 
similar extent as the respiratory chain complex III inhibitor, 
antimycin.
In addition, we confirmed the results obtained in cell-
free experiments (DNA binding, cleavage and viscosimetry 
studies) and we assessed the ability of the newly synthesised 
copper(II) complexes to bind and to damage the DNA within 
intact cancer cells. The DNA damage in A2780 cells was 
studied after treatment with 4 for 3 h, using alkaline single 
cell gel electrophoresis (Comet assay, Fig. 6B). The results 
were compared with those obtained after treatment of A2780 
cells with equitoxic concentrations of dichloro(1,10-phenan-
throline)copper(II), [Cu(phen)]. Similar to [Cu(phen)], the 
4-treated cells displayed a statistically significant increase in 
electrophoretic migration of the DNA fragments, evidenced 
by well-formed comets. To analyze the cellular DNA bind-
ing, cells A2780 were treated with complexes 1–4 for 24 h, 
as described in the experimental section, and the amount of 
copper covalently bound to the extracted DNA was deter-
mined via GF-AAS. All the complexes showed very little 
capacity to bind to the DNA in a covalent mode comparison 
to the endogenous Cu control (Fig. 5S), confirming that the 
interaction between the complexes and DNA is purely elec-
trostatic (intercalation).
These results confirmed the ability of these copper(II) 
complexes to target DNA in intact cancer cells.
Conclusions
Four copper(II)-based complexes containing the female 
steroid estradiol, were synthesised with the aim to selec-
tively target cancer cells overexpressing the estrogen recep-
tors. The complexes proved to be very effective against all 



































Fig. 5  Cellular uptake in A2780 (grey bars) and HCT-15 (black bars) 
cancer cells. A Cancer cells were incubated with 0.5  µM of copper 
complexes for 24 h, and cellular copper content was detected by GF-
AAS analysis. B Cancer cells were incubated with 0.5 µM of copper 
complex 4 for 3, 6 or 12 h, and cellular copper content was detected 
by GF-AAS analysis. Error bars indicate the standard deviation
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the cancer cell lines examined (low and sub μM  IC50 val-
ues), much more with respect to the reference drug cispl-
atin, complex 4 being the most effective one. Although no 
selectivity was observed for ER+ with respect to ER− cells 
for complexes 1–3, for complex 4 a slight difference in anti-
cancer potential towards ER+ cancer cells was underlined. 
Actually, a linear correlation was obtained in ER+ cancer 
cells between drug uptake and  IC50 values. In general, the 
antiproliferative activity and cellular uptake increased 
with the lipophilic character of Cu(II) complexes, thus 
indicating that cellular internalisation is principally due 
to a passive diffusion mechanism with a minimum role of 
the estrogen moiety. From a mechanistic point of view, 
cell-free fluorescent analyses evidenced for all copper com-
plexes strong intercalation properties but a discrimination 
between major and minor groove was not observed. Cu(II) 
complexes were redox active at the physiological range 
and were able to cleave DNA at very low concentrations 
(0.5 µM) in the presence of a reducing agent. More inter-
estingly, cell studies confirmed their ability to target DNA 
and to induce ROS production in ER+ human cancer cells.
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